Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Non-Current Assets (2016 - 2026)

OptimizeRx's Non-Current Assets history spans 16 years, with the latest figure at $112.2 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 4.26% to $112.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $457.4 million, a 102.59% increase, with the full-year FY2025 number at $112.2 million, down 4.26% from a year prior.
  • Non-Current Assets hit $112.2 million in Q4 2025 for OptimizeRx, down from $114.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for OPRX hit a ceiling of $128.9 million in Q4 2023 and a floor of $25.4 million in Q1 2022.
  • Historically, Non-Current Assets has averaged $71.3 million across 5 years, with a median of $36.8 million in 2022.
  • Biggest five-year swings in Non-Current Assets: soared 257.3% in 2023 and later fell 9.23% in 2025.
  • Tracing OPRX's Non-Current Assets over 5 years: stood at $25.9 million in 2021, then soared by 39.43% to $36.1 million in 2022, then soared by 257.3% to $128.9 million in 2023, then decreased by 9.07% to $117.2 million in 2024, then fell by 4.26% to $112.2 million in 2025.
  • Business Quant data shows Non-Current Assets for OPRX at $112.2 million in Q4 2025, $114.0 million in Q3 2025, and $115.2 million in Q2 2025.